|
|
- 2019
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyDOI: https://doi.org/10.1016/j.ccell.2019.01.003 Abstract: ？ Activated T cell signatures/populations drive response to anti-PD-1-based therapies ？ EOMES +CD69 +CD45RO + effector memory T cells are associated with response ？ EOMES +CD69 +CD45RO + expression is associated with longer PFS and tumor shrinkage ？ Non-responders with TIL-hot tumors express other immune drug target
|
